0001562180-22-007012.txt : 20221004 0001562180-22-007012.hdr.sgml : 20221004 20221004174919 ACCESSION NUMBER: 0001562180-22-007012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221004 DATE AS OF CHANGE: 20221004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Metzger Michael A CENTRAL INDEX KEY: 0001507220 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37708 FILM NUMBER: 221293420 MAIL ADDRESS: STREET 1: C/O SYNDAX PHARMACEUTICALS, INC. STREET 2: 400 TOTTEN POND ROAD, CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc CENTRAL INDEX KEY: 0001395937 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320162505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-419-1400 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2022-09-30 false 0001395937 Syndax Pharmaceuticals Inc SNDX 0001507220 Metzger Michael A C/O SYNDAX PHARMACEUTICALS, INC. 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3 WALTHAM MA 02451 true true false false Chief Executive Officer Common Stock 2022-09-30 4 M false 29606.00 8.77 A 47265.00 D Common Stock 2022-09-30 4 S false 29606.00 25.0205 D 17659.00 D Common Stock 2022-10-03 4 M false 2883.00 8.77 A 20542.00 D Common Stock 2022-10-03 4 S false 2883.00 25.011 D 17659.00 D Common Stock 2022-10-04 4 M false 1280.00 8.77 A 18939.00 D Common Stock 2022-10-04 4 S false 1280.00 25.0206 D 17659.00 D Stock Options (Right to buy) 8.77 2022-09-30 4 M false 29606.00 0.00 D 2027-02-06 Common Stock 29606.00 0.00 D Stock Options (Right to buy) 8.77 2022-10-03 4 M false 2883.00 0.00 D 2027-02-06 Common Stock 2883.00 0.00 D Stock Options (Right to buy) 8.77 2022-10-04 4 M false 1280.00 0.00 D 2027-02-06 Common Stock 1280.00 0.00 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 690,759 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested. The sale prices ranged from $25.00 to $25.15. The sale prices ranged from $25.00 to $25.03. This option is fully vested. /s/ Michael A. Metzger 2022-10-04